Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4644459
Author(s) Schaub, Anna-Chiara; Schneider, Else; Vázquez-Castellanos, Jorge F.; Schweinfurth, Nina; Kettelhack, Cedric; Doll, Jessica P. K.; Yamanbaeva, Gulnara; Mählmann, Laura; Brand, Serge; Beglinger, Christoph; Borgwardt, Stefan; Raes, Jeroen; Schmidt, André; Lang, Undine E.
Author(s) at UniBasel Brand, Serge
Year 2022
Title Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial
Journal Translational Psychiatry
Volume 12
Number 1
Pages / Article-Number 227
Mesh terms Depressive Disorder, Major, drug therapy; Dietary Supplements; Gastrointestinal Microbiome; Humans; Probiotics, therapeutic use
Abstract A promising new treatment approach for major depressive disorder (MDD) targets the microbiota-gut-brain (MGB) axis, which is linked to physiological and behavioral functions affected in MDD. This is the first randomized controlled trial to determine whether short-term, high-dose probiotic supplementation reduces depressive symptoms along with gut microbial and neural changes in depressed patients. Patients with current depressive episodes took either a multi-strain probiotic supplement or placebo over 31 days additionally to treatment-as-usual. Assessments took place before, immediately after and again four weeks after the intervention. The Hamilton Depression Rating Sale (HAM-D) was assessed as primary outcome. Quantitative microbiome profiling and neuroimaging was used to detect changes along the MGB axis. In the sample that completed the intervention (probiotics N = 21, placebo N = 26), HAM-D scores decreased over time and interactions between time and group indicated a stronger decrease in the probiotics relative to the placebo group. Probiotics maintained microbial diversity and increased the abundance of the genus Lactobacillus, indicating the effectivity of the probiotics to increase specific taxa. The increase of the Lactobacillus was associated with decreased depressive symptoms in the probiotics group. Finally, putamen activation in response to neutral faces was significantly decreased after the probiotic intervention. Our data imply that an add-on probiotic treatment ameliorates depressive symptoms (HAM-D) along with changes in the gut microbiota and brain, which highlights the role of the MGB axis in MDD and emphasizes the potential of microbiota-related treatment approaches as accessible, pragmatic, and non-stigmatizing therapies in MDD. Trial Registration: www.clinicaltrials.gov , identifier: NCT02957591.
Publisher Springer Nature
ISSN/ISBN 2158-3188
edoc-URL https://edoc.unibas.ch/88511/
Full Text on edoc Available
Digital Object Identifier DOI 10.1038/s41398-022-01977-z
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/35654766
ISI-Number MEDLINE:35654766
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.321 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/06/2024